Herzliya, Israel and Calgary, Alberta–(Newsfile Corp. – February 22, 2021) – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC Pink: INNPF) (the “Company” or “Innocan”), is pleased to announce the completion of its first full and large-scale commercial production of its SYNONY premium cosmetic line and Relief &Go OTC pain relief spray in the United States and the launch of its US Commercial Website.
Innocan has successfully completed its first commercial manufacturing run in the US of 40,000 Units of its SYNONY™ and Relief & Go™ brands. These production activities will enable the Company to deliver product to the US market, robustly and immediately.
In addition, Innocan is pleased to announce the launch of its North American commercial web-platform www.synonyshop.com. The Company, through its wholly owned subsidiary Innocan Pharma Ltd (“Innocan Israel”), has set in place agreements with world-leading companies for the fulfillment, logistics, and service required to support the activities on this website.
“Our expansion to the American market holds immense potential for Innocan”, says CEO Iris Bincovich, “Our products, that are formulated by top-tier scientists, have shown outstanding results in clinical studies, and are manufactured in state-of-the-art facilities worldwide. We are certain that these benefits will soon result in sales success in 2021 and beyond. “
The new website has been designed to offer a user-friendly experience with excellent navigation and functionality, allowing consumers to see the full product information to enhance the shopping experience. The online product distribution will be led and handled by Brandzon Co Ltd. (www.brandzon.co), a company specializing in ecommerce growth and worldwide acceleration. The Brandzon team has a proven sales track record worldwide, with global 3PL (Third Party Logistics) capabilities.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/75093
Powered by WPeMatico